Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04524871
Recruitment Status : Recruiting
First Posted : August 24, 2020
Last Update Posted : October 15, 2021
Sponsor:
Collaborators:
Sanofi
Tempest Therapeutics
Information provided by (Responsible Party):
Hoffmann-La Roche

Brief Summary:

This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with advanced liver cancers. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, modify the participant population, or introduce additional cohorts of participants with other types of advanced primary liver cancer.

Cohort 1 will enroll participants with locally advanced or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy for their disease. Eligible participants will initially be randomly assigned to one of several treatment arms (Stage 1). Participants who experience loss of clinical benefit or unacceptable toxicity during Stage 1 may be eligible to receive treatment with a different treatment combination (Stage 2). When a Stage 2 treatment combination is available, this will be introduced by amending the protocol.


Condition or disease Intervention/treatment Phase
Advanced Liver Cancers Drug: Atezolizumab Drug: Bevacizumab Drug: Tiragolumab Drug: Tocilizumab Drug: SAR439459 Drug: TPST-1120 Drug: RO7247669 Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 280 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
Actual Study Start Date : November 2, 2020
Estimated Primary Completion Date : July 10, 2024
Estimated Study Completion Date : July 10, 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Liver Cancer

Arm Intervention/treatment
Active Comparator: Stage 1: Atezolizumab + Bevacizumab
Participants will receive atezolizumab plus bevacizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
Drug: Atezolizumab
Atezolizumab will be administered at a dose of 1200 mg by IV on Day 1 of each 21 day cycle.
Other Name: Tecentriq

Drug: Bevacizumab
Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1 of each 21 day cycle.
Other Name: Avastin

Experimental: Stage 1: Atezolizumab + Bevacizumab + Tiragolumab
Participants will receive atezolizumab plus bevacizumab plus tiragolumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
Drug: Atezolizumab
Atezolizumab will be administered at a dose of 1200 mg by IV on Day 1 of each 21 day cycle.
Other Name: Tecentriq

Drug: Bevacizumab
Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1 of each 21 day cycle.
Other Name: Avastin

Drug: Tiragolumab
Tiragolumab will be administered at a dose of 600 mg by IV infusion on Day 1 of each 21 day cycle.

Experimental: Stage 1: Atezolizumab + Bevacizumab + Tocilizumab
Participants will receive atezolizumab plus bevacizumab plus tocilizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
Drug: Atezolizumab
Atezolizumab will be administered at a dose of 1200 mg by IV on Day 1 of each 21 day cycle.
Other Name: Tecentriq

Drug: Bevacizumab
Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1 of each 21 day cycle.
Other Name: Avastin

Drug: Tocilizumab
Tocilizumab will be administered at a dose of 8 mg/kg by IV infusion on Day 1 of each 21 day cycle.
Other Name: Actemra

Experimental: Stage 1: Atezolizumab + Bevacizumab + SAR439459
Participants will receive atezolizumab plus bevacizumab plus SAR439459 until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
Drug: Atezolizumab
Atezolizumab will be administered at a dose of 1200 mg by IV on Day 1 of each 21 day cycle.
Other Name: Tecentriq

Drug: Bevacizumab
Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1 of each 21 day cycle.
Other Name: Avastin

Drug: SAR439459
SAR439459 will be administered at a dose of 22.5 mg/kg by IV infusion on Day 1 of each 21 day cycle.

Experimental: Stage 1: Atezolizumab + Bevacizumab + TPST-1120
Participants will receive atezolizumab plus bevacizumab plus TPST-1120 until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
Drug: Atezolizumab
Atezolizumab will be administered at a dose of 1200 mg by IV on Day 1 of each 21 day cycle.
Other Name: Tecentriq

Drug: Bevacizumab
Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1 of each 21 day cycle.
Other Name: Avastin

Drug: TPST-1120
TPST-1120 will be administered at a dose of 1200 mg by mouth on Days 1-21 of each 21 day cycle.

Experimental: Stage 1: RO7247669 + Bevacizumab
Participants will receive RO7247669 plus bevacizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
Drug: RO7247669
RO7247669 will be administered at a dose of 2100 mg by IV infusion on Days 1 and 15 of each 28 day cycle.

Drug: Bevacizumab
Bevacizumab will be administered at a dose of 10 mg/kg by IV infusion on Days 1 and 15 of each 28 day cycle.
Other Name: Avastin




Primary Outcome Measures :
  1. Objective Response Rate (ORR) [ Time Frame: From randomization until disease progression or loss of clinical benefit (up to approximately 3-5 years) ]
    ORR, defined as the proportion of participants with a complete response or partial response on two consecutive occasions >=4 weeks apart during Stage 1, as determined by the investigator according to RECIST v1.1.


Secondary Outcome Measures :
  1. Progression Free Survival (PFS) [ Time Frame: Randomization to first occurrence of disease progression or death from any cause in Stage 1 (up to approximately 3-5 years) ]
    PFS after randomization, defined as the time from randomization to the first occurrence of disease progression or death from any cause (whichever occurs first) in Stage 1, as determined by the investigator according to RECIST v1.1.

  2. Overall Survival (OS) [ Time Frame: Randomization to death from any cause (up to approximately 3-5 years) ]
    OS after randomization, defined as the time from randomization to death from any cause.

  3. OS at Specific Timepoints [ Time Frame: Randomization to a specific timepoint, such as Month 6 ]
    OS at a specific timepoint, such as Month 6

  4. Duration of Response (DOR) [ Time Frame: First occurrence of a documented objective response to disease progression or death (up to approximately 3-5 years) ]
    DOR, defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause (whichever occurs first) in Stage 1, as determined by the investigator according to RECIST v1.1.

  5. Disease Control [ Time Frame: Randomization to end of study (approximately 3-5 years) ]
    Disease control, defined as stable disease for >=12 weeks or a complete or partial response, as determined by the investigator according to RECIST v1.1.

  6. Percentage of Participants With Adverse Events During Stage 1 [ Time Frame: Baseline through the end of the study (approximately 3-5 years) ]
  7. Percentage of Participants With Adverse Events During Stage 2 [ Time Frame: Baseline through the end of the study (approximately 3-5 years) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Stage 1

  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 within 7 days prior to randomization
  • Locally advanced or metastatic and/or unresectable hepatocellular carcinoma (HCC) with diagnosis confirmed by histology/cytology or clinically by American Association for the Study of
  • Liver Diseases criteria in cirrhotic patients
  • Child-Pugh class A within 7 days prior to randomization
  • Disease that is not amenable to curative surgical and/or locoregional therapies
  • No prior systemic treatment for HCC
  • Life expectancy >= 3 months
  • Availability of a representative tumor specimen that is suitable for determination of PD-L1 and/or additional biomarker status via central testing

Stage 1 and Stage 2

  • Measurable disease according to Response Evaluation Criteria in Solid Tumors v1.1
  • Adequate hematologic and end-organ function within 7 days prior to initiation of study treatment
  • Documented virology status of hepatitis, as confirmed by screening tests for hepatitis B virus - (HBV) and hepatitis C virus (HCV)
  • Negative HIV test at screening
  • For women of childbearing potential: agreement to remain abstinent or use contraception and for men: agreement to remain abstinent or use contraception, and agreement to refrain from donating sperm

Stage 2

  • ECOG Performance Status of 0, 1, or 2
  • Ability to initiate Stage 2 treatment within 3 months after experiencing unacceptable toxicity not related to atezolizumab or RO7247669 or loss of clinical benefit as determined by the investigator while receiving Stage 1 treatment
  • Availability of a tumor specimen from a biopsy performed upon discontinuation of Stage 1 (if deemed clinically feasible)

Exclusion Criteria:

Stage 1

  • Prior treatment with CD137 agonists or immune checkpoint inhibitors
  • Treatment with investigational therapy within 28 days prior to initiation of study
  • Treatment with locoregional therapy to liver within 28 days prior to initiation of study, or non-recovery from side effects of any such procedure
  • Untreated or incompletely treated esophageal and/or gastric varices with bleeding or at high risk for bleeding
  • Prior bleeding event due to esophageal and/or gastric varices within 6 months prior to initiation of study
  • AEs from prior anti-cancer therapy that have not resolved to Grade <= 1 or better, with the exception of alopecia of any grade
  • Inadequately controlled hypertension
  • History of hypertensive crisis or hypertensive encephalopathy
  • Significant vascular disease
  • History of hemoptysis within 1 month prior to initiation of study
  • Evidence of bleeding diathesis or significant coagulopathy
  • Current or recent use of asprin (>325 mg/day) or treatment with clopidogrel, dipyramidole, ticlopidine, or cilostazol
  • Current or recent use of full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic (as opposed to prophylactic) purpose
  • Core biopsy or other minor surgical procedure within 3 days prior to initiation of study
  • History of abdominal or tracheoesophageal fistula, GI perforation, or intra-abdominal abscess, intestinal obstruction and/or clinical signs/symptoms of GI obstruction
  • Evidence of abdominal free air not explained by paracentesis or recent surgery
  • Serious, non-healing/dehiscing wound, active ulcer, or untreated bone fracture
  • Grade >=2 proteinuria
  • Metastatic disease involving major airways/blood vessels, or centrally located mediastinal tumor masses of large volume
  • History of intra-abdominal inflammatory process
  • Radiotherapy within 28 days or abdominal/pelvic radiotherapy within 60 days prior to initiation of study with the exception of palliative radiotherapy to bone lesions within 7 days prior to initiation of study
  • Major surgery, open biopsy, or significant traumatic injury within 28 days prior to initiation of study; or abdominal surgery, abdominal interventions or significant abdominal traumatic injury within 60 days prior to initiation of study; or anticipation of need for major surgery during study or non-recovery from side effects of any such procedure
  • Chronic daily treatment with NSAID
  • Eligible only for control arm

Stage 1 and 2

  • Fibrolamellar or sarcomatoid HCC, or mixed cholangiocarcinoma and HCC
  • History of hepatic encephalopathy
  • Moderate or severe ascites
  • HBV and HCV coinfection
  • Symptomatic, untreated, or actively progressing CNS metastases
  • History of leptomeningeal disease
  • Uncontrolled tumor-related pain
  • Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures
  • Uncontrolled or symptomatic hypercalcemia
  • Active or history of autoimmune disease or immune deficiency
  • History of IPF, organizing pneumonia, drug-induced or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan
  • Active TB
  • Significant CV disease within 3 months prior to initiation of study, unstable arrhythmia, or unstable angina
  • Major surgery, other than for diagnosis, within 4 weeks prior to initiation of study, or anticipated major surgery during study
  • History of malignancy other than HCC within 5 years prior to screening
  • Severe infection within 4 weeks prior to initiation of study
  • Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study
  • Prior allogeneic stem cell or solid organ transplantation
  • Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study, or anticipation of need for such a vaccine during atezolizumab treatment or within 5 months after the final dose of atezolizumab
  • History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins
  • Known allergy or hypersensitivity to any of the study drugs or any of their excipients Treatment with systemic immunostimulatory, immunosuppressive agents within 4 weeks or 5 drug-elimination half-lives (whichever is longer) prior to initiation of study
  • Treatment with systemic immunosuppressive medication within 2 weeks prior to initiation of study
  • Patients entering Stage 2: immunotherapy-related adverse events that have not resolved to Grade 1 or better or to baseline at time of consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04524871


Contacts
Layout table for location contacts
Contact: Reference Study ID Number: GO42216 www.roche.com/about_roche/roche_worldwide.htm 888-662-6728 (U.S. and Canada) global.rochegenentechtrials@roche.com

Locations
Show Show 25 study locations
Sponsors and Collaborators
Hoffmann-La Roche
Sanofi
Tempest Therapeutics
Investigators
Layout table for investigator information
Study Director: Clinical Trials Hoffmann-La Roche
Layout table for additonal information
Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT04524871    
Other Study ID Numbers: GO42216
First Posted: August 24, 2020    Key Record Dates
Last Update Posted: October 15, 2021
Last Verified: October 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Liver Diseases
Bevacizumab
Atezolizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors